Grünenthal PRO is joining SHL Medical’s alliance partnership network to offer final assembly service for Molly® autoinjectors
Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector.
Grünenthal PRO, the contract development and manufacturing organization (CDMO) division of Grünenthal offering a range of services including final assembly of autoinjectors, is entering into a non-exclusive partnership with SHL Medical, a world-leading solutions provider of advanced drug delivery systems. Through this collaboration, Grünenthal PRO will offer final assembly, packaging and labelling of Molly® autoinjector.
Grünenthal PRO will expand its capacity for final assembly of SHL autoinjectors by installing additional assembly lines in its Origgio, Italy facility in 2026. These new pre-validated lines for Molly® 1.0 and 2.25 mL autoinjector platform will enhance speed-to-market for pharma and biotech companies, building on Grünenthal’s 10 year-experience in SHL autoinjector assembly services.
In parallel, SHL customers will benefit from access to Grünenthal PRO’s established expertise and capacity in delivering high quality, reliable contract manufacturing services.
“Speed-to-market is a decisive advantage in today’s biopharma landscape,” says Victor Barbosa, Executive Vice President of Global Operations at Grünenthal. “With our deep expertise in autoinjector final assembly and the new high-speed line launching in 2026, Grünenthal is uniquely positioned to deliver agile, large-scale solutions. Our collaboration with SHL enhances this capability, reinforcing our role as a trusted CDMO partner for injectable therapies worldwide.”
Molly® is a single-dose autoinjector built on modular platform technology that helps pharma and biotech companies reduce initial investments and accelerate timelines. Molly® boasts an unparalleled track record in combination product approvals and is designed to meet the evolving requirements of future autoinjectors.
Markus Puusepp, SHL Medical’s Chief Growth Officer, commented on the collaboration: “This new partnership builds on several years of successful project collaboration between SHL Medical and Grünenthal PRO for joint customers. We’re excited to deepen our collaboration by officially welcoming Grünenthal PRO as a strategic partner, further strengthening our trusted relationship.”
The new Molly® autoinjector assembly line to be installed by Grünenthal PRO will be procured from SHL Advantec, a sub-group of SHL Medical and global provider of high-performance, fully integrated precision tooling and advanced automation solutions for the healthcare sector and other industries.
About SHL Medical
As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients’ Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems.
Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical’s global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth.
For additional information, visit http://www.shl-medical.com/
About Grünenthal PRO
Grünenthal PRO is the contract manufacturing division of Grünenthal, offering end-to-end services in pharmaceutical assembly, packaging, and labelling. With a strong focus on injectable therapies and advanced automation, Grünenthal PRO supports global pharma and biotech companies in accelerating time-to-market and ensuring high-quality delivery. For more information, visit www.grunenthal-pro.com.
For additional information, visit www.grunenthal-pro.com
SHL
Media contact
Christine Mueller
Corporate Communications
+41 41 368 00 00
Grünenthal PRO
Media contact
Grünenthal PRO Communications
+49 (0)241 569-0
Følg pressemeddelelser fra Grünenthal Group
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Grünenthal Group
Grünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia2.6.2025 10:49:16 CEST | Press release
Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. Since 2017, Grünenthal has invested more than €2 billion in successful M&A transactions, significantly strengthening its profitability.
Maren Thurow starts as new Head Global Communications at Grünenthal20.5.2025 11:05:49 CEST | Press release
Aachen, Germany, 20th May 2025 - Maren Thurow has today assumed the role of Vice President and Head Global Communications at Grünenthal. She succeeds Florian Dieckmann, who has played a key role in evolving the company’s Communications department since 2021. In her new position, Maren will oversee Grünenthal’s communications operations across all markets and lead the team based at the company’s headquarters in Aachen. She will report directly to CEO Gabriel Baertschi.
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal24.2.2025 16:19:22 CET | Press release
Aachen, Germany & Toronto, Canada, 24 February 2025 – Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, non-opioid pain patch indicated for the management of neuropathic pain.
Grünenthal appoints Prof. Dr. Uli Brödl as Chief Scientific Officer9.1.2025 10:45:57 CET | Press release
Aachen, Germany, 09 January 2025 – Grünenthal announced today that Prof. Dr. Uli Brödl will assume the role of Chief Scientific Officer (CSO) and Member of the Corporate Executive Board, effective 01 February 2025.
Grünenthal and Averitas Pharma announce completion of recruitment for Phase III clinical trial with QUTENZA® in post-surgical neuropathic pain7.11.2024 11:26:47 CET | Press release
The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.